论文部分内容阅读
细胞因子是免疫活性细胞释放的一类低分子量蛋白质;随着其生物学性质的阐明,这些蛋白质已作为新型药物用于肿瘤治疗。本文综述细胞因子在肿瘤治疗中的潜在作用。已知有可能用于恶性肿瘤治疗的细胞因子包括白细胞介素、干扰素、肿瘤坏死因子及集落刺激因子(Colony-Stimulating Factors,CSFs) 白细胞介素(ILs):在已知的11种ILs中,多数具有治疗肿瘤的潜在应用价值,其中部分已进入临床试验。研究最多、最早进入临床试验的是IL-2,其抗肿瘤效应已得到确认。单独应用IL-2对恶性黑色素瘤和肾细胞癌有显著疗效,与LAK细胞或肿瘤浸润淋巴细胞合用疗效更佳。IL-2与其他细胞因子和化疗药物伍用可望提高抗肿瘤效应,而降低毒副作用。大剂量应用IL-2有明显毒性反应,有待探索更合理的用药方法。IL-1、IL-4、IL-5和IL-6也在体外和/或体
Cytokines are a class of low molecular weight proteins released by immunocompetent cells; these proteins have been used as novel drugs for the treatment of tumors as their biological properties are elucidated. This article reviews the potential role of cytokines in the treatment of cancer. Cytokines that are known to be useful for the treatment of malignancies include interleukins, interferons, tumor necrosis factors, and colony-stimulating factors (CSFs). Interleukins (ILs): Among the 11 known ILs Most of them have potential applications in the treatment of tumors, some of which have entered clinical trials. The most studied and the earliest entry into clinical trials was IL-2, whose anti-tumor effects have been confirmed. The use of IL-2 alone has a significant effect on malignant melanoma and renal cell carcinoma, and is better when combined with LAK cells or tumor-infiltrating lymphocytes. The use of IL-2 in combination with other cytokines and chemotherapeutic drugs is expected to improve anti-tumor effects and reduce toxic and side effects. High-dose application of IL-2 has a significant toxic response and remains to be explored for more rational drug use. IL-1, IL-4, IL-5 and IL-6 are also in vitro and/or in vivo